Company Capricor Therapeutics Inc Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Cell and Exosome-based Therapeutics
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 19/11/13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 19/11/13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Karen Krasney
LAW | General Counsel | 71 | 31/12/11 |
General Counsel | 71 | 27/02/15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 20/07/23 |
Earl Collier
BRD | Director/Board Member | 76 | 19/11/13 |
George Dunbar
BRD | Director/Board Member | 77 | 19/11/13 |
David Musket
BRD | Director/Board Member | 66 | 19/11/13 |
Frank Litvack
CHM | Chairman | 68 | 31/12/11 |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 22/07/21 |
Linda Marbán
CEO | Chief Executive Officer | 60 | 19/11/13 |
Paul Auwaerter
BRD | Director/Board Member | 62 | 12/07/23 |
Michael Kelliher
BRD | Director/Board Member | 47 | 31/08/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,502,972 | 28,874,629 ( 91.66 %) | 0 | 91.66 % |
Company contact information
Capricor Therapeutics, Inc.
10865 Road to the Cure Suite 150
92121, San Diego
+858 727 1755
http://www.capricor.comSector
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |